Hedge funds want Mallinckrodt to avoid paying $1B in opioid settlements

Mallinckrodt, a specialty drugmaker whose U.S. unit is based in St. Louis, is reportedly in discussions with hedge funds about again filing for bankruptcy to cut off about $1 billion in payments meant to assist people with opioid addiction.